主页 > 医学动态 >
【drug-news】新的精神类药物使心脏病风险加倍，
January 15, 2009, 9:03 am
Newer Antipsychotic Drugs Double Heart Risk, Just Like Older Meds
Posted by Sarah Rubenstein
The prevailing wisdom that the latest generation of antipsychotics is safer than older medicines takes a hit in the current issue of the New England Journal of Medicine.
A study comparing the drugs finds: Patients taking the newer group of drugs, called atypicals, are twice as likely to suffer sudden cardiac failure and death as nonusers. They’re just as likely to suffer those problems as if they were taking the older antipsychotics. The risk of death wasn’t high, though, at 3% for a patient treated for 10 years, as the New York Times explains it.
Sales of atypical antipsychotics have grown sharply in recent years, reaching $13 billion through the first 11 months of 2008, according to IMS Health, as quoted by the WSJ. The atypicals are supposed to help patients avoid side effects associated with the older meds, including involuntary, sometimes irreversible tremors and tics and increased risk of sudden cardiac death.
An accompanying editorial argues that use of the atypical drugs in children and elderly patients should be “reduced sharply.” (See more on risks in the Alzheimer’s patients and children.)
Jerry Avorn, a Harvard Medical School professor who has criticized drugmakers’ marketing practices and who co-authored the editorial, questioned the marketing of atypical antipsychotics as a safer alternative to older, more conventional medicines. “Now we understand that they have their own problems that are quite substantial,” he told the WSJ.
The atypical drugs used in the study were AstraZeneca’s Seroquel, Eli Lilly’s Zyprexa, Johnson & Johnson’s Risperdal and Novartis’s Clozaril. The “typical” drugs used for comparison were haloperidol and thioridazine, both generics. A Lilly spokesman told the WSJ the study provides information physicians should consider when prescribing such drugs, but added that Zyprexa has helped millions with serious mental illnesses regain control of their lives.
Zyprexa Bonus: Lilly said this morning it agreed to pay $1.4 billion to settle government investigations over its past promotion of Zyprexa. Here’s a story in the NYT.
screen.width-333)this.width=screen.width-333" width=183 height=259 title="Click to view full PJ.gif (183 X 259)" border=0 align=absmiddle> 本人已认领该文编译，48小时后若未提交译文，请其他战友自由认领 January 15, 2009, 9:03 am
Newer Antipsychotic Drugs Double Heart Risk, Just Like Older Meds
Posted by Sarah Rubenstein
新的抗精神病药物同样使心脏病风险加倍
The prevailing wisdom that the latest generation of antipsychotics is safer than older medicines takes a hit in the current issue of the New England Journal of Medic ine.
在最新一期的新英格兰医学杂志上，关于新近上市的抗精神病药物安全性优于老药的主流观点遇到了挑战。
A study comparing the drugs finds: Patients taking the newer group of drugs, called atypicals, are twice as likely to suffer sudden cardiac failure and death as nonusers. They’re just as likely to suffer those problems as if they were taking the older antipsychotics. The risk of death wasn’t high, though, at 3% for a patient treated for 10 years, as the New York Times explains it.
一项药物对比研究发现：服用新的非典型抗精神病药的病人患突发心衰的风险和死亡率是未服药人群的两倍。纽约时报解释说，尽管死亡率并不高，治疗10年的死亡率为3%，但他们似乎遇到了同服用老药时一样的问题。
Sales of atypical antipsychotics have grown sharply in recent years, reaching $13 billion through the first 11 months of 2008, according to IMS Health, as quoted by the WSJ. The atypicals are supposed to help patients avoid side effects associated with the older meds, including involuntary, sometimes irreversible tremors and tics and increased risk of sudden cardiac death.
近年来，非典型抗精神病药物的销售额直线上升，据华尔街日报援引IMS的数据，2008年的头11个月里已达到130亿$。这些非典型药物被认为是可以避免传统治疗的不良反应，包括无意识、间歇性不可逆的震颤和抽搐以及突发心衰的风险增加。
An accompanying editorial argues that use of the atypical drugs in children and elderly patients should be “reduced sharply.” (See more on risks in the Alzheimer’s patients and children.)
随行社论建议非典型抗精神病药物在儿童和老年患者中的使用应当锐减。（在阿尔兹海默病人和儿童中的风险更大）
Jerry Avorn, a Harvard Medical School professor who has criticized drugmakers’ marketing practices and who co-authored the editorial, questioned the marketing of atypical antipsychotics as a safer alternative to older, more conventional medicines. “Now we understand that they have their own problems that are quite substantial,” he told the WSJ.
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-03-01 05:12
医学,生命科学网